Moses Sing Sum Chow, Pharm.D., FCP, FCCP
Director of CADRE and overall coordinator for clinical outcome studies.
Dr. Chow has over 30 years of experience in transitional research and clinical studies in the areas of cardiovascular pharmacotherapy and application of pharmacokinetics/ pharmacogenomics. His recent research work has been devoted to the development of conventional drugs and herbal medicines (Chinese medicines). He has also established a strong net work with Asian countries, especially China where he served as Director of the Pharmacy School in Hong Kong for 8 years. He has published over 300 articles in peer reviewed journals plus 6 book chapters. He has been active in numerous professional organizations, including serving as President of The American Chinese Pharmaceutical Association, Founding President of Asian Association of Schools of Pharmacy, Secretary of the American College of Clinical Pharmacology, Editorial Board member of .a number of journals, as well consultant of NIH(NHLBI) and USP.
Guru V. Betageri, Ph.D.
Overall coordinator for formulation studies.
Guru Betageri, Ph.D., is Professor of Pharmaceutical Sciences at Western University of Health Sciences. His expertise is in the area of liposomal drug delivery systems and solid dosage forms. He has obtained grants from Federal agencies and over 40 pharmaceutical companies. He was instrumental in the formulation and development of several products on the market. Dr. Betageri teaches Pharmaceutics to Pharm.D. students and preformulation, product development and novel drug delivery systems to graduate students. He has published more than 50 research papers and presented over 100 papers, and is co-editor of the book, “Liposome Drug Delivery.” Dr. Betageri is the holder of three US patents.
Nissar A. Darmani, Ph.D.
Overall coordination for pharmacological studies.
Dr. Darmani has extensive research experience pertaining to developmental effects of drugs of abuse on the newborn, serotonergic mechanisms of cocaine’s actions, mode of action of antidepressant drugs, adaptive mechanisms of serotonergic 5-HT2 receptor functions, the role of delta-9 -THC and synthetic cannabinoids as well as other antiemetics on chemotherapy- and radiotherapy-induced vomiting.
Yin Huang, Ph.D.
Overall coordinator for genomic studies.
Dr. Huang’s past research has concentrated on the genetic mechanisms by which tumors show differential response to anticancer drugs with the aim of developing strategies for preventing or overcoming resistance. Since membrane transporters facilitate the flux of drugs and important natural compounds into and out of cells, they play critical roles in sensitivity and resistance to anti-cancer drugs. Dr. Huang and her colleagues seek to determine whether genetic variation in transporters contributes to variation in sensitivity and resistance to anti-cancer drugs.
Jeffrey Wang, Ph.D.
Overall coordinator for bioanalysis and pharmacokinetic studies.
Dr. Wang has considerable experience in research pertaining to reversible lipidization and PEGylation of proteins and peptides, oral delivery of peptide drugs, drug uptake and transport in epithelial cells, solid phase peptide and organic synthesis, bio-conjugation chemistry, novel penetration enhancer design, rational design and synthesis of anti-cancer agents, analytical assay development, pharmacokinetics and drug metabolism.